Source: Benzinga

Gemphire Therapeutics: Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals

ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions.As previously announced, Gemphire's stockholders voted to approve the proposals required to complete the merger transaction. In connection with these approvals, the Board of Directors of Gemphire has approved a reverse stock split of Gemphire's common stock at a ratio of one new share for every 25 shares outstanding, which is expected to become effective immediately prior to the consummation of the merger. Immediately following the closing, the combined company will be renamed "NeuroBo Pharmaceuticals, Inc.", and is expected ...Full story available on Benzinga.com

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Stephen Gullans's photo - President & CEO of Gemphire Therapeutics

President & CEO

Stephen Gullans

CEO Approval Rating

90/100

Read more